UTILISATION DE DÉRIVÉS ACIDE NICOTINIQUE RIBOSIDES OU DE DÉRIVÉS NICOTINAMIDE RIBOSIDES, ET DÉRIVÉS RÉDUITS DE CES DERNIERS, EN TANT QUE PRÉCURSEURS DE L'AUGMENTATION DU NAD+
DELLINGER, Ryan,RHONEMUS, Troy,MORRIS, Mark,ERICKSON, Aron,CASSIER, Hadi,MIGAUD, Marie, E.
申请号：
EP17786649
公开号：
EP3445359A4
申请日:
2017.04.20
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
Compositions are provided including nicotinic acid riboside (“NAR”), and derivatives thereof including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinic acid (“NAR triacetate” or “NARTA”)； or derivatives of a reduced form of nicotinic acid riboside (“NARH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (“NARH triacetate” or “NARH-TA”)； or derivatives of nicotinamide riboside (“NR”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinamide (“NR triacetate” or “NRTA”)； derivatives of a reduced form of nicotinamide riboside (“NRH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (“NRH triacetate” or “NRH-TA”)； or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. Methods of using the compounds above to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (“NAD+”) or NADH in cells and tissues for improving cell and tissue survival or overall cell and tissue health are provided.
